November 7, 2008: NanoSight Ltd., a nanoparticle characterization company, has completed a new round of financing that will provide £925,000 to enable the company to expand the business with the development of new products and sales channels in the US market.

Having successfully weathered the start-up process during the past four years, NanoSight can become more robust with investment in personnel, technical support and development of the underlying technology.

“I am just delighted to have closed this round at the right price and at a time when finance is becoming so much harder to obtain. We have raised more than twice the minimum we had set for ourselves, and this offers us a good degree of freedom,” says CEO, Jeremy Warren. “Our principal investment opportunities are in development of next-generation NanoSight instruments and expansion of our operations in the USA.”

“Success to date has come from technology that allows the analysis of our customers’ products on a particle-by-particle basis rather than relying on an ensemble or averaged measurement,” he adds. “Our approach using Nanoparticle Tracking Analysis provides nanoscience researchers with powerful information to better design products. The systems we shall produce over the coming year will go much further in the additional independent variables they can measure, and, once again, particle-by-particle.”

Scientific advisor to investors, Professor Tony Atkinson said: “NanoSight’s science provides a unique method of detecting and analyzing nanoparticles, giving analytical data not previously available. This cutting edge technology addresses a large and growing market. The capability to detect and analyze biological nanoparticles provides the means to address a number of new markets in the diagnostic space.”